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Gene expression profiles of circulating leukocytes correlate with
renal disease activity in IgA nephropathy.
Background. The goal of these studies was to explore the
possibility of using gene expression profiles of circulating leuko-
cytes as a functional fingerprint of nephritic disease activity.
Methods. This feasibility study utilized IgA nephropathy
(IgAN) as a model system. Genes differentially expressed
in IgAN patients were identified by Affymetrix GeneChip
microarrays, and compared with gene expression of focal
segmental glomerulosclerosis (FSGS), minimal change disease,
antineutrophil cytoplasmic antibody (ANCA) glomeru-
lonephritis, and with healthy volunteers. Of the genes
identified, 15 transcriptionally up-regulated were validated
in a larger cohort of patients using TaqMan polymerase
chain reaction (PCR). To test whether increased expression of
these genes correlated with disease activity, cluster analyses
were performed utilizing the TaqMan PCR values. Taking a
mathematical approach, we tested whether gene expression
values were correlative with kidney function, as reflected by
serum creatinine and creatinine clearance values.
Results. We identified 15 genes significantly correlative with
disease activity in IgAN. This gene signature of IgAN patients’
leukocytes reflected kidney function. This was demonstrated
in that mathematically generated theoretical values of serum
creatinine and creatinine clearance correlated significantly with
actual IgAN patient values of serum creatinine and creatinine
clearance. There was no apparent correlation with hematuria
and proteinuria. The expression levels of this same gene set
in ANCA glomerulonephritis or Lupus nephritis patients were
not correlative with serum creatinine or creatinine clearance
values.
Conclusion. These data indicate that leukocytes carry infor-
mative disease-specific markers of pathogenic changes in renal
tissue.
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Disease diagnosis and evaluation of disease severity
using gene expression patterns are quickly becoming re-
ality rather than conjecture. Indeed, the fields of bioin-
formatics and molecular epidemiology have emerged as
methods to utilize genomics data derived from large-scale
sequencing efforts such as the Human Genome Project
[1]. Microarrays are now in use to fingerprint biologic
or pathologic processes [2, 3]. The value of evaluating
gene expression profiles has been documented in ani-
mal models of disease. For example, gene expression in
leukocytes can distinguish among a variety of experimen-
tal cerebral disorders [4]. Despite the enormous promise
of this revolutionary technology, its practical applica-
tion and relevance to the clinical arena has not been
widely studied. If patterns of altered gene expression can
be established using white blood cells of patients, this
could lead to a new approach to diagnostics that is mini-
mally invasive. This prompted us to take the first steps in
investigating whether or not gene expression patterns of
circulating leukocytes could be used as functional finger-
prints of events that occur in the kidney of patients with
IgA nephropathy (IgAN).
Here, we test the hypothesis that changes in gene ex-
pression patterns in circulating leukocytes of patients
with the nephritic syndrome IgAN will correlate with
renal disease activity. IgAN, a condition recognized
worldwide as one of the most common primary glomeru-
lonephropathies, is characterized by the presence of IgA
in the glomerular mesangium [5, 6]. Glomerular filtration
and renal blood flow often is progressively impaired by
advancing glomerular and tubulointerstitial injury [7]. To
screen for genes pertinent to disease activity in IgAN pa-
tients, we performed microarray chip profiling on periph-
eral blood leukocytes and compared the results with those
from healthy volunteers and with results from three other
glomerular diseases. A subset of the identified genes were
verified in a larger cohort of patients and controls us-
ing TaqMan polymerase chain reaction (PCR). Cluster
analysis of these data demonstrates a correlation between
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gene transcript levels and disease activity. Moreover, we
show that gene expression changes reflect serum creati-
nine and creatinine clearance values in these patients, as
determined by multiple regression analyses.
METHODS
Patients
The diagnosis of primary IgAN was based on re-
nal biopsy findings of IgA-dominant or codominant
mesangial immune deposits by immunofluorescence
microscopy. Measures of disease activity included mi-
croscopic hematuria (0 to 4+), 24-hour protein ex-
cretion, serum creatinine, and calculated glomerular
filtration rate (GFR) (Cockcroft and Gault’s equation).
The pathology indices included the degree of glomerular
mesangial and endocapillary proliferation and the degree
of glomerular or interstitial fibrosis, each scored on a scale
of 0 (none) to 4+ (severe). An arbitrary classification
scheme that closely corresponds with our clinical practice
was devised by two of us (R.J.F. and J.C.J.), which incor-
porates pathology and clinical disease indicators. Classifi-
cation of degree of clinical disease activity was as follows:
Mild disease activity was defined as the presence of hema-
turia with <1 g proteinuria with normal renal function,
with minimal evidence of scaring on biopsy. Moderate
disease activity was defined as the presence of hematuria
with >1 g proteinuria and stable renal function (i.e., a
stable serum creatinine), with some glomerular scarring
and interstitial fibrosis. The severe disease category was
defined as renal insufficiency with or without hematuria
and >1 g of proteinuria, with marked glomerular scarring
and interstitial fibrosis, but also included patients with
substantial hematuria and acute renal failure. Patients
were considered in remission if there was no evidence of
hematuria, <1 g of proteinuria and no evidence on renal
biopsy of active glomerular inflammation (i.e., hypercel-
lularity, necrosis or cellular crescents). Patients diagnosed
with IgAN enrolled in the study (N = 22) (22 white; 11
males and 11 females) ranged in age from 7 to 79 years. Of
these, five patients donated a second sample later total-
ing 27 samples analyzed. Eight of the RNA samples were
consumed in the microarray chip analyses. The remain-
ing 19 samples were utilized for TaqMan PCR analyses.
Only one sample (IgA 2a) was sufficient in amount for
both microarray and TaqMan PCR analyses. The time
lapse between biopsy and leukocyte had a median of
10 months with a mean of 141/2 months and a range
of 1 week to 42 months. Healthy volunteers (N = 32)
(32 white; 17 males and 15 females) ranged in age from
18 to 46 years. Patients diagnosed with antineutrophil
cytoplasmic antibody (ANCA) glomerulonephritis (N =
24) (22 white and two African Americans; 13 males and
11 females), systemic lupus erythematosus (SLE) (N =
18) (seven white, nine African American, two Asian; one
male and 17 females), focal segmental glomerulosclerosis
(FSGS) (N = 5) (two white and three African American;
three males and two females), and minimal change dis-
ease (N = 6) (two white, three African American, and
one Asian; four males and two females) were included in
the study for disease-related comparisons.
Leukocyte isolation
Approximately 20 mL of blood was drawn into four
7 mL ethylenediaminetetraacetic acid (EDTA) vacutain-
ers. Leukocytes were isolated from whole blood by lysis of
red blood cells by incubation for 11 minutes in a hypotonic
ammonium chloride solution at a 9-to1 ratio. Following a
wash with 1× Hank’s balanced salt solution (HBSS), the
cells were resuspended in RNA Stat 60 at a concentration
of ∼107cells/mL (Tel Test, Inc., Friendswood, TX, USA).
The RNA Stat 60/cell solution was stored in −70◦C for
up to 1 week before RNA processing.
RNA isolation procedure
As per protocol from Tel Test, Inc., RNA was isolated
from the cell/RNA Stat 60 mixtures by addition of 0.2 mL
of chloroform to remove proteins. The aqueous phase
containing the RNA was isolated by centrifugation, and
the RNA precipitated with 0.5 mL of isopropanol. The
RNA pellet was washed once with 75% ethanol and then
resuspended in 100 lL of nuclease-free water (Promega,
Madison, WI, USA). As per RNeasy protocol (Qiagen,
Valencia, CA, USA), RNA solution was applied to col-
umn for purification, DNase treated for 15 minutes and
eluted in 30 to 50 lL of nuclease-free water. RNA was
treated with RNA secure (Ambion, Austin, TX, USA)
after both the initial resuspension in nuclease-free water
and after the column elution. RNA was quantified and
purity determined by obtaining the absorbance at 260 nm
and 280 nm using spectrophometric methods. The RNA
integrity was determined by visualization of the 28S and
18S RNA bands using 0.5 lg of RNA on a 1% agarose
gel stained with Sybr Gold (Molecular Probes, Eugene,
OR, USA). RNA was then stored at −70◦C.
Microarray data processing
Affymetrix Human 60KMicroarray GeneChip of
genes microarrays were utilized for identification of genes
differentially expressed (methodologies described in de-
tail by Affymetrix, Palo Alto, CA, USA). This proce-
dure was performed at Gene Logic, Inc., as previously
described [8]. Briefly, hybridization to the Affymetrix
GeneChip HuGeneFL array, and raw data collection
was done exactly as described by Tackels-Horne et al [9].
The raw data were analyzed with Affymetrix software,
GeneChip version.3.0 and Experimental data mining
tool version1.0. S-Plus was used to perform the analysis
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of variance (ANOVA) principal component analysis
(PCA) as previously described [8], and hierarchical clus-
tering analyses identified ∼341 genes as differentially reg-
ulated (153 up and 188 down) in IgAN patients. Arrays
were globally scaled to an average intensity of 2500. A
value of 200 was assigned to all intensity measurements
below 200 before differences in intensities were calcu-
lated. Three parameters were used for analysis, aver-
age difference intensity change, difference call, and fold
change. Gene expression levels that varied less than 1.5-
fold relative to the biologic base line or had a difference
call of “no change,” as determined by the GeneChip
algorithms, were considered unchanged. Further anal-
ysis was based on those genes whose expression levels
changed between IgA patients and controls. Known con-
stitutively expressed genes were used to normalize the
data from different microarray experiments. Briefly, the
expression levels of the selected genes were scaled to a
“standard experiment” and the geometric mean of the
scaling factors was calculated. This value served as the
normalization factor for all genes represented on the mi-
croarray. Genes were clustered within categories using
the Statistica, Gene Cluster, Treeview programs [10].
TaqMan PCR quality control and analyses
TaqMan PCR was performed to validate the mi-
croarray chip results and to examine a subset of these
genes in a larger cohort of patients. TaqMan primers
and probes were designed using Primer Express soft-
ware (version 1.0) or version 1.5 (Macintosh) (Applied
Biosystems, Foster City, CA, USA). TaqMan PCR re-
actions were performed in MicroAmp Optical 384-well
Reaction Plates. Fluorescence emission was monitored
using the ABI Prism 7900 Sequence Detection System,
and this information was automatically converted to am-
plification plots using the ABI Prism 7900 Sequence
Detection System software. The log RNA concentration
versus the cycle number at specific threshold (Ct) value
was plotted. A line was fit to the data and the slope and the
linear regression values were determined. Only primer
sets that met the following criteria were used for quanti-
tative reverse-transcription (RT)-PCR (TaqMan) anal-
ysis: (1) a slope value between −3.0 and −3.7, (2) a linear
regression value of 0.90 or greater, (3) a no template con-
trol (NTC) Ct value above 35, and (4) an NTC Ct no
closer than 3 Cts from the lowest concentration of RNA
analyzed. Only sample RNAs with Ct values within the
linear range as determined by this qualification process
were accepted. Disease specific RNA samples were used
for TaqMan PCR analyses. To circumvent inter-plate
variability, we tested one gene per plate using all RNA
samples. Fold-change in expression was determined by
the Ct method: Briefly, the Ct value was determined
by subtracting the Ct value for the housekeeping gene
cytochrome C oxidase from the Ct value for the gene
of interest. Cytochrome C usage as a normalizing gene
was based on comparisons of microarray data analyses
of a battery of housekeeping genes, which showed cy-
tochrome C expression to be relatively constant among
the samples, whereas glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was not (data not shown). Arbi-
trarily, a control sample was selected and the remainder
of samples was adjusted by subtracting that Ct value.
Then, the fold-change was calculated using the follow-
ing equation: fold-change = 2(−Ct) and the mean of
these calculated values was determined. The differences
in expression of genes in patients’ samples are calculated
by dividing the actual fold-change by the adjusted mean
of the normals to give a relative expression level. The Stu-
dent t test was performed on adjusted normal and IgAN-
fold expression change values to determine significance
(P < 0.05). Duplicate patient samples were omitted from
statistical analyses.
Patients were divided into two groups, mild/moderate
and severe, and expression levels were analyzed to de-
termine statistical difference from normal controls using
ANOVA and ranked ANOVA analyses for significant dif-
ferences (P < 0.05). Only genes that were different by ei-
ther Student t test or the ANOVA analyses were selected
for further study. All statistical analyses were performed
using SAS statistical program (SAS, Durham, NC, USA).
The quantitative values of Q-RT-PCR results were sub-
jected to cluster analysis performed by computational cal-
culations with Statistica (Statsoft, Inc., Tulsa, OK, USA)
and Excel (Microsoft, Redmond, WA, USA).
Regression and correlation analyses
For regression modeling, we fit the data to develop a
formula that consists of a sum of predictor effects, with
each predictor coming from a covariate. We applied sta-
tistical methods to find relationships between disease-
related gene expression values and clinical parameters
using a standard computational spread sheet program
[11–14]. To select the disease-related genes as indepen-
dent predictor variables, we used the Ru value:
Ru = 1 − (1 − R2)(n + k + 1)/(n − k − 1)
where R is the multiple correlation coefficient, n is fold-
change TaqMan PCR value, and k is the degree of free-
dom of regression. The multiple regression procedure
was used to estimate a linear equation for identification
of gene combinations yielding a Ru value closest to 1:
Y = a + b1 ∗ X1 + b2 ∗ X2 + · · · + bp ∗ Xp
where Y is either serum creatinine or creatinine clear-
ance, X1, X2 · · · XP are the TaqMan PCR values, a is the
fixed value and b1, b2 · · · bp are the regression coefficients
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for each gene. Transcript levels outside of normal val-
ues were identified by comparing patient TaqMan PCR
values to the mean value of 20 healthy volunteers. The
efficiency index of a particular gene is the range of cal-
culated fold-change values (max-min value of TaqMan
PCR data) times the coefficient for curve fit from the
multiple regression analysis. Ep was calculated using as
follows:
Ep = bp x
RESULTS
Identification of genes differentially expressed in IgAN
Our experimental strategy was to first identify genes
differentially expressed in IgAN using microarray chip
technology and then to utilize this information to se-
lect a subset of IgAN-up-regulated genes for testing by
quantitative TaqMan PCR in a larger cohort of patients
and controls. Patient selection for microarray chip studies
included representatives of mild, moderate, and severe
(Table 1). To aid in identification of transcripts specifi-
cally altered in IgAN (N = 9), comparisons were made
with healthy volunteers (normals) (N = 12), patients with
ANCA glomerulonephritis (N = 5), FSGS (N = 5) and
minimal change disease (N = 6). We identified 153 tran-
scriptionally up-regulated and 188 down-regulated genes.
For example, interleukin-8 (IL-8) was found to be signif-
icantly increased 2.42-fold in IgAN (Fig. 1).
From a list of identified, up-regulated genes (fold-
increase 1.5- to 3.6-fold) in IgAN patients (Table 2), we
selected 14 statistically significant genes by ANOVA and
ranked ANOVA analyses (P < 0.05) for further study,
with addition of galectin 3 because of its carbohydrate-
binding capacity. Limiting the number of genes is nec-
essary for additional analyses and for the mathematical
formula outputs of this study. Three sets of PCR primers
for each gene were developed and characterized for pro-
ficiency and specificity. Transcript levels of these 15 genes
were analyzed by TaqMan PCR in 15 new IgAN patients
(three of which donated a sample twice within the year)
in addition to IgA 2a, whose RNA sample was sufficient
to use in both microarray and TaqMan  PCR analyses
(N = 19 samples). Table 3 lists the differences in expres-
sion of genes in patients’ samples, which were calculated
by dividing the actual fold-change by the adjusted mean
of the normals to give a relative expression level. The
results confirmed the microarray results, thus verifying
that these particular genes are abnormally expressed un-
der the pathologic conditions of IgAN in some patients,
when compared to the mean expression levels of healthy
volunteers.
Increased expression clusters with IgAN patients
To address the issue of whether this gene profile cor-
relates with disease activity, we performed cluster analy-
Table 1. Leukocyte donors for microarray chip analyses
Age/gender/ Serum Disease
Patient race creatinine activity
N1679 22/M/W 1.1 NA
N1680 26/F/W 1.1 NA
N1708 44/F/W 1.1 NA
N3538 37/F/W 1.1 NA
N3539 20/M/W 1.1 NA
N3543 20/M/W nd NA
N3544 24/M/W nd NA
N5094 42/F/W nd NA
N5095 31/F/W nd NA
N5096 22/M/W nd NA
N5097 30/F/W nd NA
N5098 32/M/W nd NA
IgA 1b (1183) 42/M/W 1.3 Remission
IgA 19 (4205) 33/F/W 1.0 Mild
IgA 21 (5089) 50/F/W 1.1 Mild
IgA 4a (3540) 21/M/W 1.0 Moderate
IgA 20 (5092) 32/M/W 1.9 Moderate
IgA 2aa(5090) 17/M/W 0.9 Moderate
IgA 24 (4204) 33/F/W 2.6 Severe
IgA 22 (5091) 32/F/W 1.7 Severe
IgA 25 (5093) 20/M/W 2.9 Severe
ANCA 1180 63/F/W 6.4 Severe
ANCA 1648 54/F/W 2.2 Moderate
ANCA 1650 79/M/W 4.6 Severe
ANCA 2165 50/F/W 0.8 Moderate
ANCA 3534 75/M/W 1.8 Moderate
FSGS 1649 44/F/B 2.9 Severe
FSGS 1652 14/M/B 1.0 Moderate
FSGS 2166 28/F/W 0.7 Moderate
FSGS 2269 7/M/B 0.5 Moderate
FSGS 2270 31/M/W 2.3 Moderate
MC 1647 15/F/B 1.4 Severe
MC 1651 38/M/B 1.0 Moderate
MC 1678 25/M/W 0.9 Severe
MC 2267 53/M/W 1.0 Moderate
MC 2268 20/F/B 1.2 Moderate
MC 3535 25/M/A 0.9 Severe
Abbreviations are: ANCA, antineutrophil cytoplasmic antibodies; FSGS, focal
segmental glomerulosclerosis; MC, minimal change; NA, not applicable.
aThis patient sample was used in both microarray and TaqMan polymerase
chain reaction (PCR) analyses. Samples collected from the same patient over the
course of disease are indicated (a and b).
ses, based on TaqMan PCR fold-change data (Table 3).
These hierarchical clustering algorithms provide a gen-
eral view of the association of the genes with the clinical
parameters of IgAN. As depicted in Figure 2, the clus-
tering output highlights two primary clusters, one with
the majority of IgAN patients. Lower levels of the den-
drogram (the shorter branches denoting higher degrees
of similarity) revealed four distinct subgroups. Interest-
ingly, clinical parameters of proteinuria and hematuria do
not appear to dictate clustering patterns (Fig. 2), nor does
age, gender, or race (all subjects in this set of experiments
were white). Instead, we observed a general linkage with
disease activity. We found that some normal individuals
clustered with IgAN patients (normals 1, 2, 3, and 4), and
some patients clustered with the normals (IgA 11, IgA 2b,
IgA 8, IgA 5b, and IgA 5a). This could not be explained
by any of the known variables. However, it is remark-
able that replicate samples from the same patient, whose
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Fig. 1. An example of results from microarray chip analyses indicating that interleukin-8 (IL-8) transcript levels were statistically higher in patients
with IgA nephropathy (IgAN), as compared to normals and patients with antineutrophil cytoplasmic antigen (ANCA), focal segmental glomerular
sclerosis (FSGS), and minimal change (MnCh) nephritic disorders. Patient characteristics are given in Table 1.
disease status had not changed, clustered tightly together
as observed with IgA 16a and b. The same applies for IgA
5a and b in cluster F.
The gene signature of IgAN patients’ leukocytes
reflects kidney function
We took our analyses a step further and asked if we
could correlate the gene expression data with kidney
function determined by measurements of serum crea-
tinine concentrations. We first performed multiple re-
gression analyses to generate a mathematical model for
approximation of serum creatinine concentration. Anal-
yses of reliability of regression (see Methods section)
grouped the genes that yielded a Ru value of 0.854, in-
dicating that genes BTG2, NCUBE1, FLJ2948, SRPK1,
LZS, GIG-2, and IL-8 correlate mathematically with
serum creatinine levels (Fig. 3A). Using these genes a
formula was developed: serum creatinine = 1.631676 +
(0.198639 × BTG2) + (−0.69285 × NCUBE) +
(0.026568 × FLJ294) + (0.41222 × SRPK1) + (0.35276
× LZS) + (−0.16758 × GIG-2) + (−0.14398 × IL-8).
Substitution of individual TaqMan PCR values for each
of these seven genes, a theoretical serum creatinine level
was calculated for each of 18 patients. Graphic represen-
tation of the calculated value versus the actual clinical
value indicates that expression of these genes is correla-
tive with serum creatinine values (Fig. 3B).
Not all overexpressed genes reflect a detrimental ef-
fect. Some overexpressed genes may have a positive
effect, when considering the patient’s recovery process,
or a protective effect when considering disease progres-
sion. We calculated the efficiency index of each of the
seven genes described above. An efficiency index value
of zero would indicate that expression of that gene does
not depend on serum creatinine concentration. In con-
trast, a positive or negative value would indicate that the
expression increases or decreases linearly with changes in
serum creatinine concentration. Higher levels of BTG-2
correspond to higher levels of serum creatinine, while
NCUBE1 is inversely proportional (Fig. 3C).
Next, we asked how well the IgAN gene expression
data correlate with creatinine clearance. Creatinine clear-
ance takes into account the patient’s age, gender, and
size. The mathematical iterations described above were
performed to select genes from the group of 15 that gave
the best Ru value, 0.773 (Fig. 4A). The eight genes iden-
tified, PMAIP1, B3GNT5, SRPK1, SSI-3, LZS, GIG-2,
AXUD1, and PTGS2, were used to generate a for-
mula that would provide a theoretical creatinine clear-
ance value; creatinine clearance = 25.52501 + (31.07027
× PMAIP) + (−35.7845 × B3GNT) + (52.24351 ×
SRPK1) + (8.056434 × SSI-3) + (33.42925 × LZS) +
(−26.3692 × GIG-2) + (−23.037 × AXUD1) + (47.70423
× PTGS2). The actual creatinine clearance values (rang-
ing from ∼168.8 to 48.0) and the theoretic values were
comparative in every case (Fig. 4B), with the largest de-
viation seen in patient IgA 9 with values of 57.9/actual
versus 80.4/theoretic.
Analysis of efficiency index for each gene indicate that
PMAIP1, SRPK1, SSI-3, LZS, and PTGS2 are linearly
correlated with higher creatinine clearance values, imply-
ing that these genes may provide a protective effect, while
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Table 2. Top known genes up-regulated in IgA nephropathy (IgAN) patients’ leukocytes
Name Accession Name Accession
Transcription factor Signaling
Egr 1 (early growth response) X52541 M AP KKK3 (kinase) U78876
Egr 2 AA486027 SGK kinase R97759
GOS2 (lymphocyte G0/G1 gene) T52813 GADD34 AA251320
KIAA1100 AA411433 OSR1 (oxidative-stress responsive 1) AA039663
Transforming protein fos-B L49169 Ubiquitin enzyme 7 interacting protein 3 AA447671
MYB binding protein (P160) 1a N49846 HM74 putative chemokine receptor D10923
NCUBE1 AA256528
Proteases and inhibitors NUP98 (nucleoporin 98 kD) AA505118
Cathepsin K T67463 SREBP cleavage-activating protein D83782
SLPI (antileukoproteinase) AA026641 SOS1 (son of sevenless homolog 1) W74256
LYZ (lysozyme) M21119 GRN (granulin) X62320
FLJ22948 fis, clone KAT09449 AA447740
Membrane associated AXUD1 (AXIN1 up-regulated 1) T16484
ATP-binding A (ABC1), 7 H45265  B3GNT5 AA043551
Adaptor-related protein alpha2 H28956 GIG2 (G-protein-receptor-induced) AA236455
ATP synthase subunit T49146 PMAIP1 (PMA-induced protein 1) AA262439
Membrane assoc protein 17 AA253473 SSI-3 (suppressor of cytokine signaling) R69417
Mitochondrial membrane protein AA121962 UBE1 (ubiquitin-activating enzyme E1) M58028
Phospholipid scramblase AF008445
Nucleic acid binding
Secreted proteins DDX34 DEAD/H Box 34 R48810
IL-8 M28130 KIAA1100 AA411433
Inducible cytokine A4 M69203 SRPK1 (SFRS protein kinase) R78142
VNN3 Vanin 3 AA461448 BTBD1 [BTB (POZ) domain containing] R69336
HDAC5 (histone deacetylase 5) AA496574
Vasoactive mediators FHL3 (four and a half LIM domains) AA460438
PTGS2 (COX-2) U04636
Cell cycle Miscellaneous
BTG family, member 2 Y09943 SLC25A1 (solute carrier family 25) W86850
BHLHB2 T40999 SLC16A5 (solute carrier family 16) AA421374
Amplified in ostersarcoma N25082 Wolf-Hirschhorn syndrome-like AA286863
PTMS (parathymosin) W90032 KIAA1536 protein AA412555
MIR (myosin regulatory interacting AA129373
protein)
IDN3 AA490868
NELL2 (NEL-like 2) H23584
HLX1 (H2.0-like homeo box 1) M60721
Denotes genes selected for real-time polymerase chain reaction (PCR) analyses.
Table 3. Adjusted TaqMan polymerase chain reaction (PCR) values (fold-change above the mean of the normals)
Patient BTG2 PMAIP B3GNT NCUBE FLJ294 SRPK1 SSI-3 LZS GIG-2 AXUD1 PTGS2 EGR1 GOS2 Gal3 IL-8
1a Mild 1.88 2.02 4.15 1.79 1.40 1.36 1.12 1.32 1.53 2.40 2.37 1.80 11.02 0.61 1.55
2a Mild 1.04 2.08 3.27 2.38 0.68 2.06 2.71 1.98 2.89 1.54 2.05 1.83 4.74 1.08 2.77
3 Mild 0.85 3.74 2.91 1.06 0.41 0.86 1.07 1.11 3.39 1.32 1.63 1.65 4.49 0.46 2.27
4b Moderate 1.52 2.07 0.95 1.51 1.36 0.97 1.36 1.21 1.90 1.25 1.71 0.91 1.25 0.75 1.65
5a Moderate 1.09 1.51 1.59 2.05 1.02 1.75 2.02 0.56 2.42 1.38 1.29 1.13 0.80 0.81 0.99
5b Moderate 1.16 1.27 1.86 2.54 1.60 2.01 1.88 1.03 1.10 1.76 0.56 0.75 0.94 1.03 1.13
6 Moderate 2.69 3.92 5.03 2.24 0.88 1.57 3.84 0.89 2.11 4.79 3.74 1.22 5.83 0.40 2.41
7 Moderate 1.44 1.34 0.95 0.94 0.66 1.49 0.87 1.06 3.67 1.70 1.79 0.81 1.56 0.41 3.08
8 Moderate 0.97 0.74 1.28 1.51 0.88 0.85 0.76 0.74 1.34 1.03 0.78 0.50 0.40 0.58 1.26
9 Moderate 0.72 1.11 1.03 1.27 0.95 0.80 1.58 1.19 1.10 1.42 0.52 0.61 2.41 0.50 1.43
2b Severe 1.19 1.40 1.04 2.10 1.15 0.65 0.48 2.00 1.71 0.57 0.96 0.99 0.66 1.18 0.30
11 Severe 1.29 0.76 4.66 1.31 65.31 1.72 1.16 2.37 0.82 2.07 0.64 1.39 0.78 1.36 0.89
12 Severe 5.00 4.29 6.16 2.97 1.60 1.23 3.04 2.60 2.87 4.05 3.56 4.86 3.09 0.96 5.76
13 Severe 2.17 1.06 3.50 1.44 0.48 1.29 1.76 1.70 1.69 1.98 1.91 0.97 4.81 0.82 0.97
15 Remission 0.58 1.17 2.11 0.91 1.30 1.04 0.88 0.58 1.31 1.45 0.77 0.98 4.34 0.61 1.61
16a Remission 2.14 2.65 3.78 2.56 0.42 2.34 4.76 1.92 3.66 3.82 1.63 3.04 4.07 0.59 1.48
16b Remission 3.13 3.66 8.18 3.35 0.56 3.45 5.70 3.44 4.80 9.19 5.44 11.79 9.19 0.79 4.05
17 Remission 2.89 2.57 1.52 2.02 2.20 1.50 2.23 1.44 1.91 3.88 1.65 1.01 6.43 1.30 3.97
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Fig. 3. Theoretical serum creatinine values, generated using a mathematically derived formula using gene expression levels, correlate with actual
serum creatinine levels. (A) Regression modeling was performed to select disease related genes as independent predictor variables. Seven genes
(underlined) gave the best-fit Ru value of 0.854, based on P values. (B) This method was applied to find correlation between disease related gene
expression values and clinical serum creatinine values, using a standard computational spread sheet program. (C) The efficiency index of a particular
gene is the range of calculated fold-change values [Max-min value of TaqMan polymerase chain reaction (PCR) data] times the coefficient for
curve fit from the multiple regression analysis. A positive value implies that a reduction of this transcript may have beneficial effects in reducing
serum creatinine levels.
the opposite would be true for B3GNT5, AXUD1, and
GIG-2 (Fig. 4c).
The gene set is specifically indicative of disease
activity in IgAN patients
Is the leukocyte gene expression profile for IgAN spe-
cific for this disease or is this particular profile dictated
by the general state of renal insufficiency caused by any
disease? To test this we used TaqMan PCR to determine
the expression levels of the 15 genes identified as part of
the IgAN profile in two other glomerular diseases (i.e.,
ANCA glomerulonephritis or lupus nephritis). The fold-
change values (data not shown) were substituted into the
mathematical model developed for IgAN. For theoretic
values to be correlative, the actual serum creatinine value
minus the theoretical value must be <0.5 or the actual
creatinine clearance value minus the theoretical value
must be <25. In ANCA patients, the gene expression-
generated values were correlative in five of 19, while in
lupus patients nine of 19 were correlative, when com-
paring serum creatinine concentrations (Table 4). Theo-
retic creatinine clearance values were correlative in four
of 19 ANCA patients and one of 19 lupus patients. The
data indicate that the mathematical model established for
IgAN has little relationship to clinical values in ANCA
glomerulonephritis and lupus nephritis patients. These
data are compellingly, suggestive that gene expression
patterns in leukocytes can serve as specific fingerprints of
a particular disease that can be used to distinguish disease
activity.
DISCUSSION
This work establishes for the first time that gene ex-
pression changes in circulating leukocytes can be use-
ful in assessing in IgAN patients. Using microarray
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Fig. 4. Theoretic creatinine clearance values, generated using a mathematically derived formula based on gene expression levels, correlate with
actual creatinine clearance values. (A) Regression modeling was performed to select disease related genes as independent predictor variables.
Eight genes (underlined) gave the best-fit Ru value of 0.773, based on P values. (B) This method was applied to find a correlation between disease
related gene expression values and creatinine clearance values, using a standard computational spread sheet program. (C) The efficiency index
of a particular gene is the range of calculated fold-change values [Max-min value of TaqMan polymerase chain reaction (PCR) data] time the
coefficient for curve fit from the multiple regression analysis. A negative value implies that restoration of transcript levels to normal may have
positive effects on creatinine clearance.
technology, we identified genes differentially expressed
in IgAN that were not up-regulated in ANCA glomeru-
lonephritis, FSGS, or minimal change disease. TaqMan
PCR authenticated the microarray data and computa-
tional studies using these PCR values provided a method
to generate an accurate and reproducible estimate of clin-
ical parameters and disease activity.
We were astonished to find that calculations based on
expression levels of a particular gene group could ac-
curately approximate clinical measures of kidney func-
tion in 100% of the IgAN patients. This correlation of
the expression of these particular genes with renal im-
pairment appears to be specific for IgAN because it was
not observed in patients with lupus nephritis or ANCA
glomerulonephritis. Given these results, we are perplexed
as to why the cluster analyses using this gene group re-
sulted in several patients who clustered with the healthy
volunteers. Looking at the patients’ characteristics, there
were no apparent differences that would explain these
results.
Also of interest, included in our study is a pediatric pa-
tient (IgA 8, 7 years old) whose gene expression profile
did not cluster with the adult IgAN patients. For addi-
tional comparisons with the adult values, the Cockcroft-
Gault equation was applied (although not conventionally
applicable), and we found this pediatric patient’s creati-
nine clearance value correlated with the theoretic value.
However, once the researcher realizes that clustering is
simply an exploratory data analysis tool and not a typi-
cal statistical test, the random patient that falls into the
“normal” cluster is understandable. Cluster analysis takes
large amounts of information and sorts it into manage-
able, meaningful piles. For example, initially each ob-
ject exists in a class by itself. Now imagine that, in very
small steps, we “relax” our criterion as to what is and
is not unique. Put another way, we lower our threshold
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Table 4. IgA nephropathy (IgAN)-related gene expression profiles do not reflect clinical serum creatine levels or creatinine clearance of patients
with antineutrophil cyctoplasmic antigen (ANCA) disease or systemic lupus erythematosus (SLE)
Serum creatinine mg/dL
Patient Patient
(age/gender/race) Actual Theoretic (age/gender/race) Actual Theoretic
ANCA 1 (54/M/W) 2.2 0.47 SLE 1 (63/F/W) 0.86 −0.29
ANCA 2 (15/F/W) 0.8 1.19 SLE 2 (60/M/W) 1.6 0.03
ANCA 3 (43/M/W) 0.9 0.57 SLE 3 (37/F/A) 0.6 0.10
ANCA 4 (45/M/B) 2.1 0.44 SLE 4 (32/F/W) 1.1 1.04
ANCA 5 (52/F/W) 1.7 1.72 SLE 5 (47/F/B) 1.8 0.64
ANCA 6 (55/M/W) 2.6 0.62 SLE 6 (33/F/B) 0.9 −0.91
ANCA 7 (67/M/W) 1.7 1.21 SLE 7 (23/F/W) 1 0.6
ANCA 8 (36/M/W) 3.8 1.05 SLE 8 (21/F/B) 1.6 1.12
ANCA 9 (53/M/W) 0.9 1.16 SLE 9 (24/F/W) 1 0.58
ANCA 10 (43/M/W) 2.7 1.16 SLE 10 (28/F/B) 0.7 1.16
ANCA 11 (50/F/B) 9.2 2.06 SLE 11 (28/F/B) 0.9 0.33
ANCA 12 (64/M/W) 1.1 2.01 SLE 12 (35/F/W) 0.8 −0.41
ANCA 13 (55/M/W) 2.4 1.29 SLE 13 (22/F/B) 0.8 0.54
ANCA 14 (24/F/W) 1 1.53 SLE 14 (44/F/B) 4.4 1.24
ANCA 15 (2/M/W) 2.4 0.77 SLE 15 (57/F/B) 1.1 1.22
ANCA 16 (45/F/W) 1.1 1.57 SLE 16 (48/F/B) 0.7 0.74
ANCA 17 (33/F/W) 1 0.46 SLE 17 (20/F/A) 5.2 1.17
ANCA 18 (36/F/W) 0.7 1.59 SLE 18 (24/F/W) 0.9 1.20
ANCA 19 (61/F/W) 4.5 1.66
Creatinine clearance
Patient Actual Theoretic Patient Actual Theoretic
ANCA 1 42.1 137.24 SLE 1 62.1 10.68
ANCA 2 100.9 150.76 SLE 2 53.9 336.93
ANCA 3 116.2 196.09 SLE 3 110.8 244.29
ANCA 4 48.8 105.36 SLE 4 63.4 130.14
ANCA 5 33.4 308.40 SLE 5 33.4 157.94
ANCA 6 35.2 195.42 SLE 6 76.8 165.21
ANCA 7 46.7 118.32 SLE 7 75.6 141.75
ANCA 8 29.5 224.54 SLE 8 48 92.89
ANCA 9 104.2 102.36 SLE 9 74.9 222.30
ANCA 10 38.7 225.45 SLE 10 103.4 211.01
ANCA 11 6.3 234.90 SLE 11 80.3 175.04
ANCA 12 74.5 184.79 SLE 12 84.7 235.62
ANCA 13 38.2 113.64 SLE 13 95.3 144.56
ANCA 14 74.9 85.09 SLE 14 14.1 107.43
ANCA 15 53 38.67 SLE 15 48.7 197.53
ANCA 16 55.8 61.87 SLE 16 84.8 132.82
ANCA 17 69.1 128.40 SLE 17 14.9 229.61
ANCA 18 30 159.60 SLE 18 83.2 98.29
ANCA 19 18.4 75.81
Denotes theoretic values that coorelate with actual values; correlative criteria: serum creatinine–actual vs. predictive must be <0.5; creatinine clearance–actual vs.
predictive must be <25.
regarding the decision when to declare two or more ob-
jects to be members of the same cluster. As a result,
we link more and more objects together and aggregate
larger and larger clusters of increasingly dissimilar el-
ements. Finally, in the last step, all objects are joined
together. Thus, the resulting clusters are by nature not
homogeneous. Outliers within the clusters are difficult to
interpret. These may stem from the fact that the similari-
ties/dissimilarities between different clusters may pertain
to or be caused by somewhat different subsets of vari-
ables. Nevertheless, and in support of the efficacy of our
studies, in two instances cluster analysis of samples from
the same individual, collected as much as a year apart,
gave results that fell into the same cluster.
The pathophysiologic basis for the correlation between
this gene expression profile in leukocytes and renal func-
tion in IgAN is not revealed by our studies, but the
data should provide a fertile ground for exploration. It
was interesting to make comparisons of our microarray
analysis of total leukocytes with a published expression
profile of bacterially exposed neutrophils. Newburger,
Subrahmanyam, and Weissman [15] utilized a gel-based
method to display 3′ end fragments of cDNAs on isolated
neutrophils. Comparisons revealed that some gene fam-
ilies are represented in both studies [mitogen-activated
protein (MAP) kinase, GADD, and ubiquitin pathway,
GOS, Ras-related] and both studies had cyclooxygenase-
2 (COX-2) and IL-8. Bacteria are known to starts flares
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of active disease in IgAN and this overlap in genes, al-
though small, may reflect bacterially induced changes in
our IgAN patients. These similarities imply that the neu-
trophil population is responsible in part for the altered
leukocyte expression profile in our patients. However,
further studies are needed for verification.
The lack of correlation between the IgAN expression
profile and renal function in ANCA glomerulonephritis
and lupus patients indicates that the altered gene expres-
sion is not dictated merely by the renal insufficiency. Thus,
the expression profile, most likely is a reflection of altered
leukocyte function that is more directly related to the
pathologic events in the kidney in IgAN. This is in accord
with the earlier observations by our research group of an
expression profile of leukocyte genes that is characteristic
of ANCA glomerulonephritis patients [16]. Medications
might, and probably do, affect leukocyte gene expression.
Vasculitis and SLE is usually treated with corticosteroids,
while most patients with IgAN do not receive steroids. On
the other hand, angiotensin-converting enzyme (ACE)
inhibitors or angiotensin receptor inhibitors are proba-
bly more widely used in patients with IgAN. This is an
area that remains to be studied.
Although familial links in our IgAN patient popula-
tion have been ruled out, a familial form of IgAN has
been linked to a gene on chromosome 6q22-23 [17]. In-
terestingly, one of the genes that clustered with IgAN
in our studies was NCUBE1, which is a gene on chro-
mosome 6q. The product of this gene is a member of a
family of ubiquitin-conjugating enzymes. These enzymes
selectively target proteins for proteasomal degradation
by the covalent attachment of ubiquitin moieties [18].
The efficiency index analyses indicate NCUBE1 to be
inversely related to disease activity (i.e., increased ex-
pression was associated with lower creatinine concentra-
tions). The data do not prove causality but suggest there
may be a relationship between this gene and the induction
or progression of IgAN. Information from mathematical
modeling of this type may identify potential drug targets.
The information gleaned from this type of analysis is the
identification of potential drug targets such as NCUBE1,
which if increased may have a beneficial effect on serum
creatinine levels, at least in IgAN patients.
The era of bioinformatics and computational biology
allows inferences about causality of disease at the genetic
level. New reports are surfacing daily that describe the
efficacy and utility of microarray information [19]. By
combining the patients’ clinical data with gene cluster
bioinformatics, we were able to cluster specific genes with
biologic outcomes. These studies were not designed as
large population analyses to prove disease specificity or
as predictors of renal function. Large population stud-
ies will be needed to determine if in fact leukocyte gene
expression profiles can be used as bioindicators for di-
agnostics and for predicting disease responses. As we
consider the efficacy versus pitfalls of revolutionary new
technologies on the horizon, as stated by King and Sinha,
“the potential payoff remains large” [20].
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